Research record · source-linked
Publications in oncology and clinical research
The records below were returned by the PubMed author query Poltoratskiy[Author]. This is a bibliographic index. Use the complete source record when verifying authorship, contribution or affiliation.
17records in the current PubMed result
checked 18 August 2026
checked 18 August 2026
Bibliography
Newest to earliest
- 2026The New England Journal of Medicine
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
PMID 41104938 · PubMed ↗ - 2025Clinical Lung Cancer
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study
PMID 40887341 · PubMed ↗ - 2025European Journal of CancerPublication correction
Corrigendum to the phase III OCTAVA trial publication
PMID 40886565 · PubMed ↗ - 2025European Journal of Cancer
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
PMID 40795521 · PubMed ↗ - 2025Journal for ImmunoTherapy of Cancer
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma
PMID 39904560 · PubMed ↗ - 2024Clinical Cancer Research
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
PMID 37801329 · PubMed ↗ - 2022ESMO Open
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
PMID 35279527 · PubMed ↗ - 2021ESMO Open
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study
PMID 34543864 · PubMed ↗ - 2021Frontiers in Oncology
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
PMID 34307179 · PubMed ↗ - 2021Lung Cancer
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
PMID 33387727 · PubMed ↗ - 2021The Lancet Oncology
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
PMID 33285097 · PubMed ↗ - 2020Lung Cancer
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
PMID 32961445 · PubMed ↗ - 2019The Lancet
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
PMID 31590988 · PubMed ↗ - 2017Advances in Gerontology
The geriatric status in patients with breast cancer in the conditions of comorbidity
PMID 29322734 · PubMed ↗ - 2017JAMA
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial
PMID 28492898 · PubMed ↗ - 2014BMC Cancer
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer
PMID 24766732 · PubMed ↗ - 2013Cancer Cytopathology
Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides
PMID 23408463 · PubMed ↗